BioCentury
ARTICLE | Clinical News

Seattle Genetics gets $30M milestone for EU approval of Adcetris in first-line Hodgkin lymphoma

February 15, 2019 7:50 PM UTC

Seattle Genetics Inc. (NASDAQ:SGEN) will receive a $30 million milestone payment from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) triggered by the European Commission's decision to expand the label of Adcetris brentuximab vedotin to include previously untreated CD30-positive stage IV Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine.

Adcetris is also approved in Europe for previously treated Hodgkin lymphoma, cutaneous anaplastic large cell lymphoma and cutaneous T-cell lymphoma...

BCIQ Target Profiles

CD30